Continuous glucose monitoring for adults with type 2 diabetes in underserved communities
Official title: Continuous Glucose Monitoring in an Underserved Population: Impact on Glucose Control, Patient Reported Outcomes, Healthcare Utilization, and Long Term Complications
Run by Tulane University · NCT07135531 · Data updated 2026-11-12
This project will test whether giving continuous glucose monitors to uninsured or Medicaid-insured adults with type 2 diabetes who take daily insulin helps them manage their blood sugar better than standard fingerstick monitoring.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Tulane University Academic / other |
| Locations | 1 site (New Orleans, Louisiana) |
| Status | Recruiting |
| Started | March 19, 2026 |
| Main results expected | July 2027 |
| Study ends | July 2027 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT07135531 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 years with type 2 diabetes, HbA1c ≥ 7.5%, taking at least one insulin injection daily, covered by Medicaid or uninsured and established with local clinics in the New Orleans area who can consent in English.
✕Probably not a fit
People with type 1 diabetes, current CGM or insulin pump users, those with advanced kidney disease (eGFR <40), pregnant patients, or those unable to attend local clinic visits are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, open-label pilot comparing continuous glucose monitoring (CGM) versus standard self-monitoring in underserved adults with type 2 diabetes on daily insulin. After a two-week run-in, participants are randomized to the CGM group or the self-monitoring group and all receive diabetes education, with six months of follow-up. Participants in the control group may opt to wear a CGM for three months after the six-month follow-up. The pilot will test feasibility and provide preliminary data on glycemic outcomes to inform a larger multicenter trial.
Why it matters
Potential benefit: If successful, CGM could improve blood sugar control and reduce diabetes-related disparities among uninsured and Medicaid patients.
How similar studies have gone: Randomized trials in insulin-treated type 2 diabetes have demonstrated improved glycemic control with CGM, but few have focused specifically on uninsured or Medicaid populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-75 years * Type 2 diabetes mellitus * HbA1C ≥ 7.5% * At least on 1 insulin injection therapy daily * Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas * Patients with Medicaid or free care or uninsured * Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study Exclusion Criteria: * Type 1 diabetes mellitus * Currently on CGM or using insulin pump * Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) \<40 * Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate * The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement * Pregnant
Where it's running
-
University Medical Center
New Orleans, Louisiana, United States Recruiting
Study contacts
- Principal investigator: Shaveta Gupta, MD — Tulane University
- Study coordinator: Neha Upadhyay, BDS,MPH
- Email: nupadhyay@tulane.edu
- Phone: 5049889803
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remote-patient monitoring in diabetes care shows real-world outcomes
A real-world, pre-post observational study at Steno Diabetes Center Copenhagen tests whether adding remote-patient-monitoring within the EHR can maintain glycemic outcomes over two years for about 12,000 people with diabetes compared with prior ambulatory care.
-
Using Omnipod 5 in France: one-year real-world follow-up (Optimal-B)
This study will see if the Omnipod 5 automated insulin delivery system helps children and adults with type 1 diabetes in France improve glucose control, quality of life, and reduce acute diabetes complications over 12 months.
-
Connecting clinics and community partners to address unmet social needs for people with diabetes in rural Kentucky
This project tries a clinic–community program to help adults with diabetes in two rural Kentucky communities get services for unmet social needs.
-
iLet Bionic Pancreas started through primary care for adults on insulin
This project will test whether starting the iLet Bionic Pancreas through primary care helps adults with insulin-treated type 1 or type 2 diabetes lower their A1c more than routine care over 13 weeks.
-
Effect of Olive Pomace Oil on Blood Sugar Levels
This study is testing if adding olive pomace oil to meals can help people with type 2 diabetes or those at risk manage their blood sugar levels better.
-
Biobank for studying ALS and Alzheimer's diseases
This study is collecting blood, skin samples, and health information from people to see how genetics might help us understand and find treatments for ALS and Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.